Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid biotran...
Remimazolam is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.
Ronald Reagan UCLA Medical Center, Department of Anesthesiology & Perioperative Medicine, Los Angeles, California, United States
Pusan National University Yangsan Hospital, Yangsan, Please Select, Korea, Republic of
The Affiliated Hospital of Yangzhou University., Yangzhou, Jiangsu, China
Wonkwag UH, Iksan, Jeollabukdo, Korea, Republic of
Wonkwang University hospital, Iksan, Korea, Republic of
Samsung Medical Center, Seoul, Korea, Republic of
Tongji Hospital, Wuhan, Hubei, China
Daegu Catholic University Medical Center, Daegu, Korea, Republic of
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.